Follow
tuğrul elverdi
tuğrul elverdi
İstanbul Üniversitesi - Cerrahpaşa , Cerrahpaşa Tıp Fakültesi
Verified email at istanbul.edu.tr
Title
Cited by
Cited by
Year
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
A Salihoglu, T Elverdi, I Karadogan, S Paydas, E Ozdemir, G Erdem, ...
Annals of hematology 94, 415-420, 2015
462015
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
T Elverdi, AE Eskazan
Drug design, development and therapy, 1251-1258, 2019
442019
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion
AE Eskazan, D Eyice, EA Kurt, T Elverdi, FF Yalniz, A Salihoglu, MC Ar, ...
Leukemia Research 38 (7), 781-787, 2014
402014
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data …
S Ongoren, AE Eskazan, V Suzan, S Savci, I Erdogan Ozunal, S Berk, ...
Hematology 23 (4), 212-220, 2018
352018
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate
AE Eskazan, M Ayer, B Kantarcioglu, D Arica, N Demirel, D Aydin, ...
British journal of haematology 167 (1), 139-141, 2014
302014
Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec
AE Eskazan, S Sadri, D Keskin, M Ayer, B Kantarcioglu, N Demirel, ...
Clinical Lymphoma Myeloma and Leukemia 17 (12), 804-811, 2017
282017
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia
AE Eskazan, T Elverdi, FF Yalniz, A Salihoglu, MC Ar, S Ongoren Aydin, ...
Leukemia & Lymphoma 55 (12), 2935-2937, 2014
272014
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study
OM Akay, M Ozbalak, M Pehlivan, B Yildiz, A Uzay, TN Yigenoglu, ...
Hematological Oncology 39 (4), 498-505, 2021
152021
The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results
K Sonmezoglu, B Vatankulu, T Elverdi, R Akyel, ME Erkan, M Halac, ...
Nuclear medicine communications 38 (1), 76-83, 2017
132017
Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
Y Erbilgin, AE Eskazan, O Hatirnaz Ng, A Salihoglu, T Elverdi, S Firtina, ...
Leukemia & lymphoma 60 (1), 200-207, 2019
122019
Retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience
Ş Öngören, AE Eşkazan, S Berk, T Elverdi, A Salihoğlu, MC Ar, Z Başlar, ...
Turkish Journal of Hematology 34 (4), 291, 2017
112017
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis
E Öztürk, M Özbalak, S Berk, I Erdoğan, E Avşar, A Dolgun, M Çetiner, ...
Leukemia & lymphoma 57 (5), 1211-1214, 2016
112016
Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
T Elverdi, MD Özer Çerme, T Aydın, AE Eşkazan
Expert Review of Clinical Pharmacology 14 (10), 1183-1188, 2021
92021
Vincristine as an adjunct to therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a single-institution experience
S Öngören, A Salihoğlu, T Apaydın, S Sadri, AE Eşkazan, MC Ar, ...
Balkan Medical Journal 35 (6), 417, 2018
82018
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
A Bazarbachi, A Boumendil, H Finel, I Khvedelidze, ...
Leukemia 36 (6), 1646-1653, 2022
72022
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia
ET Simsek, AE Eskazan, M Cengiz, MC Ar, S Ekizoglu, A Salihoglu, ...
Journal of Clinical Pathology 69 (9), 810-816, 2016
72016
Efficacy and safety of imatinib treatment in elderly patients with chronic myeloid leukemia: real-life data and a single-center experience
AE Eşkazan, D Özmen, M Öztaş, F Bektaş, EA Bayraktar, S Sadri, ...
Clinical Lymphoma Myeloma and Leukemia 21 (8), 549-557, 2021
62021
Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country
A Murt, T Elverdi, AE Eskazan, A Salihoglu, MC Ar, S Ongoren, Z Baslar, ...
Annals of Hematology 99, 2671-2677, 2020
52020
Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?
AE Eskazan, I Erdogan, S Berk, FF Yalniz, T Elverdi, A Salihoglu, T Soysal
Leukemia & Lymphoma 56 (10), 2995-2996, 2015
52015
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
M Tütüncü, S Demir, G Arslan, Ö Dinç, S Şen, T Gündüz, C Uzunköprü, ...
Multiple Sclerosis and Related Disorders 75, 104761, 2023
32023
The system can't perform the operation now. Try again later.
Articles 1–20